Venture capital deals

Karyopharm Therapeutics Inc., a Natick, Mass.-based developer of nuclear transport modulators, has raised $48.2 million in Series B funding. Delphi Ventures was joined by an undisclosed “private investor.”

Effector Therapeutics, a San Diego-based developer of small molecule selective translation regulators for cancer, has raised $45 million in Series A funding. Backers include U.S. Venture Partners, Abingworth, Novartis Venture Funds, SR One, Astellas Venture Management, Osage University Partners and Mission Bay Capital.

Alteryx Inc., an Irvine, Calif.-based provider of strategic analytics, has raised $12 million in new VC funding from Toba Capital and return backer SAP Ventures.

Zyme Solutions, a Redwood Shores, Calif.-based provider of channel data management solutions, has raised $5 million in new VC funding from Susquehanna Growth

Sign up for Dan’s daily email newsletter on deals and deal-makers:

Subscribe to Well Adjusted, our newsletter full of simple strategies to work smarter and live better, from the Fortune Well team. Sign up today.